

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07C 51/09, C08F 22/14, C12N 15/25</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/30326</b>
		(43) International Publication Date: 3 October 1996 (03.10.96)

(21) International Application Number: PCT/US96/04348

(22) International Filing Date: 29 March 1996 (29.03.96)

(30) Priority Data:  
08/413,806 30 March 1995 (30.03.95) US(71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF  
PENNSYLVANIA [US/US]; Center for Technology Trans-  
fer, Suite 300, 3700 Market Street, Philadelphia, PA 19104-  
3147 (US).(72) Inventor: WU, Gary, D.; 28 Whitemarsh Road, Ardmore, PA  
19003 (US).(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane  
Massey Licata, Woodland Falls Corporate Park, Suite 201,  
210 Lake Drive East, Cherry Hill, NJ 08002 (US).(81) Designated States: CA, JP, European patent (AT, BE, CH, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).**Published**  
*With international search report.*

(54) Title: DIFFERENTIATING AGENTS FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASES

## (57) Abstract

A method for decreasing the inflammation associated with a chronic inflammatory intestinal condition in a patient is provided wherein the patient is administered an effective amount of a differentiating agent.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## DIFFERENTIATING AGENTS FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASES

This application is a continuation-in-part of Application Serial No. 08/387,116 filed February 13, 1995.

### 5 BACKGROUND OF THE INVENTION

Neoplastic disease is characterized by inappropriate cell proliferation relative to the rate of differentiation. A variety of agents which can induce transformed cells to express characteristics of a differentiated state and cease  
10 proliferating have been identified for use in the treatment of human cancers. Such agents include relatively simple polar/apolar compounds, retinoic acid and its derivatives, vitamin D<sub>3</sub> and its derivatives, tumor promoters, inhibitors of RNA or DNA synthesis including several agents used as cytotoxic  
15 therapy for cancers, growth factors, such as hematopoietic-cell growth factors, proteases, and hormones. The basic defect in cancers involves an imbalance in the relationship between proliferation of precursor cells and the differentiation of these cells. Differentiation factors can normalize the  
20 relationship of proliferation to differentiation. Consideration of a use for differentiating factors in the treatment of human cancers is based largely upon in vitro studies that have demonstrated the effectiveness of these agents in inducing a wide variety of transformed cell lines to  
25 differentiate and stop growing. The successful treatment of human acute promyelocytic leukemia by retinoic acid established that cytodifferentiation therapy may have utility in the

- 2 -

treatment of human malignancies. The clinical evaluation of additional differentiating agents has begun more recently.

Butyric acid has been shown to induce cytodifferentiation *in vitro* in a wide variety of neoplastic cells. Chen, Z. and Brutman, T.R. *Cancer Res.* 1994, 54:3494-3499. The potential utility of this agent as an antineoplastic has been limited, however, by the apparent difficulty in achieving effective concentrations of butyric acid *in vivo*. Chen and Brutman studied the effect of the prodrugs monobutylin and tributyrin *in vitro* in inducing differentiation of human myeloid leukemia HL60 cells and murine erythroleukemia cells. Butyric acid, monobutylin and tributyrin all induced erythroid differentiation of erythroleukemia. However, on a molar basis tributyrin was 3- to 4-fold more potent than butyric acid, whereas monobutylin was much less potent than butyric acid. Based upon these experiments, it was suggested that tributyrin may be a promising candidate as a prodrug of butyric acid, either as a sole agent or in combination with other agents, for cytodifferentiation therapy of human leukemia and other malignancies and possibly for patients with  $\beta$ -hemoglobinopathies. Chen, Z. and Brutman, T.R. *Cancer Res.* 1994, 54:3494-3499.

Another differentiating agent, sodium phenylacetate, has been evaluated as an alternative to cytotoxic chemotherapy in the treatment of cancer. Phenylacetate has been demonstrated to promote maturation of various human leukemic cell lines. In addition, its use has been suggested in the treatment of prostate cancer. Samid et al. *J. Clin. Invest.* 1993, 91:2288-2295. Phenylacetate has been demonstrated to suppress tumor growth and promote differentiation in experimental models. Thibault et al. *Can. Res.* 1994, 54:1690-1694. It has also been shown that sodium phenylacetate and its precursor, sodium 4-phenylbutyrate, enhance fetal hemoglobin production in cultured erythroid progenitor derived from normal donors and patients with sickle cell anemia and  $\beta$ -thalassemia.

There is also increasing evidence to suggest that 1,25-dihydroxy vitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>), or calcitrol, has important

- 3 -

physiological effects on growth and differentiation in a variety of malignant and nonmalignant cell types. One of the earliest demonstrations of the antiproliferative effects of 1,25-(OH)<sub>2</sub>D<sub>3</sub> was with the HL-60 human promyelocytic leukemia cell line. Treatment with physiological doses of 1,25(OH)<sub>2</sub>D<sub>3</sub> suppressed cell growth and induced monocytic differentiation. Similar growth-inhibiting and differentiation-inducing effects have been demonstrated *in vitro* in other cell types including normal human bone cells, and in malignant cell lines derived from breast, malignant melanoma, histiocytic lymphoma and colon carcinoma. Halline et al. *Endocrinology* 1994, 134(4):1710-1717.

Differentiating agents such as 1,25(OH)<sub>2</sub>D<sub>3</sub> and analogs thereof, have also been used in the treatment of diseases related to disordered epidermal differentiation. In addition to producing vitamin D, epidermal cells (keratinocytes) make 1,25(OH)<sub>2</sub>D<sub>3</sub>, contain 1,25(OH)<sub>2</sub>D<sub>3</sub>, and respond to 1,25(OH)<sub>2</sub>D<sub>3</sub> with changes in proliferation and differentiation. Bikle, D.D. and Pillai, S. *Endocrine Reviews* 1993, 14(1):3-19. 1,25(OH)<sub>2</sub>D<sub>3</sub> has been found to inhibit IL-1 $\alpha$  induced IL-8 production and mRNA expression in keratinocytes, fibroblasts and PBMC, but not in endothelial cells. Larsen et al. *Biochem. Biophys. Res. Commun.* 1991, 176(3) 1020-1026. Calcipotriol is a vitamin D<sub>3</sub> analog which also inhibits cell proliferation and enhances cell differentiation. Calcipotriol has pharmacodynamic properties similar to those of calcitriol, the active metabolite of vitamin D<sub>3</sub>. In several *in vitro* models both calcipotriol and calcitriol inhibit cell proliferation and enhance cell differentiation. Both drugs reduce cell numbers, total DNA content and incorporation of radiolabeled thymidine into DNA and increase the number of human keratinocytes with cornified envelopes and activity of enzyme-caused, protein crosslinking in the envelopes. In patients with psoriasis, calcipotriol also reduces dermal proliferation and enhances differentiation in lesional skin. Murdoch, D. and Clissold, S.P. *Drugs* 1992, 43(3):415-429.

- 4 -

It has now been found that differentiating agents are also useful in the treatment of intestinal inflammatory diseases. Differentiating agents which alter the state of proliferation and ultimately the differentiation of colonic epithelial cells reduce the inflammation associated with intestinal diseases such as ulcerative colitis.

#### SUMMARY OF THE INVENTION

An object of the present invention is to provide a method of treating intestinal inflammatory diseases in a patient by administering to a patient an effective amount of a differentiating agent.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a Northern blot of total RNA from preconfluent undifferentiated Caco-2 cells stimulated with IL-1 $\beta$  which is hybridized with a cDNA probe for IL-8 and then rehybridized with a cDNA probe for 7S to demonstrate the loading and integrity of the RNA in each lane.

Figure 2 is a Northern blot of the same RNA samples as shown in Figure 1 which is hybridized using a probe for a fragment of the CCAAT/Enhancer Binding Protein delta isoform, an immediate gene product of the inflammatory response, and then rehybridized with a probe for 7S ribosomal RNA to demonstrate the loading and integrity of the RNA in each lane.

#### DETAILED DESCRIPTION OF THE INVENTION

The normal mammalian small intestine is lined by an epithelium that is continuously renewed by proliferation of stem cells in intestinal crypts, migration of daughter cells from crypts onto villi, and extrusion of cells into the intestinal lumen at the tips of villi. Migration of enterocytes from crypts to villi is coincident with the appearance of a differentiated phenotype. Accordingly, the intestinal mucosa represents a dynamic, complex epithelium that is spatially segregated into a proliferating, undifferentiated compartment referred to as the crypts and a nonproliferating,

- 5 -

differentiated compartment referred to as the villi. Gordon, J.I. *J. Cell. Biol.* 1989, 108:1187-1194. A similar compartmentalization occurs in the large intestine with undifferentiated proliferating epithelial cells located in the lower 2/3rds of the colonic crypts and undifferentiated cells located in the upper 3rd as well as on the surface mucosa. Risio, M. *J. Cell. Biochem.* 1992, 16G:79-87; Barnard et al. *Gastroenterology* 1993, 105:67-73.

During intestinal inflammatory states, however, there is an alteration in this pattern of epithelial differentiation. There is an increase in epithelial proliferation with an expansion of cell populations in an undifferentiated state, referred to as crypt hypertrophy, as well as a decrease in cells exhibiting a differentiated phenotype, referred to as villus atrophy. This histologic pattern has been observed in many small intestinal inflammatory states such as celiac disease, pouchitis, tropical sprue and giardiasis. MacDonald, T.T. *Ann. NY Acad. Sci.* 1992, 664:202-209. A hyperproliferative state also occurs in the colonic epithelium during inflammatory states such as ulcerative colitis and parasitic infections. Risio, M. *J. Cell. Biochem.* 1992, 16G:79-87.

It is believed that the expansion of the crypt cell compartment helps to perpetuate the intestinal inflammatory response. Indirect evidence suggests that the state of epithelial cell differentiation may determine whether or not intestinal epithelia are capable of responding to an inflammatory stimulus. Studies have shown that only undifferentiated proliferating crypt cells are capable of producing inflammatory cytokines such as IL-8 (Izzo et al. *Gastroenterology* 1994, 106:A239) and IL-1 $\beta$  (Radema et al. *Gastroenterology* 1991, 100:1180-1186). Furthermore, the production of neutrophil chemoattractive substances such as IL-8 exclusively by the crypt epithelium may explain why transmigration of neutrophils in acute intestinal inflammatory states occurs in the crypt compartment referred to as crypt abscesses. In addition, induction of MHC class 2 expression by



- 6 -

the intestinal epithelium in response to interferon  $\gamma$  or other inflammatory states such as GVDH or *Trichinella spiralis* infection occurs only in the proliferating crypt epithelium in both the small and large intestine. Bland, P. *Immunology Today* 5 1988, 9:174-178.

The histologic appearance of active ulcerative colitis includes an intense lymphoplasmocytosis limited to the mucosa and submucosa which may be associated with a neutrophilic infiltrate invading the colonic epithelium, in particular the 10 crypt abscess. This intense neutrophilic infiltrate observed with acute ulcerative colitis has been associated with elevated mucosal levels of interleukin-8 and circulating antibodies in patients with active ulcerative colitis as compared to normal controls and patients with active Crohn's disease. Hawkey et 15 al. *Agents Actions* 1992, 92:C23-26. Ulcerative colitis is therefore categorized as a disorder of the colonic mucosa. Several investigators have shown that the colonic epithelium is in a hyperproliferative state with expansion of the proliferative compartment from the lower crypt to the upper 20 crypt extending to the surface epithelium. Biasco et al. *Cancer Res.* 1984, 44:5450-5454; Serafini et al. *Gut* 1981, 22:648-652. This hyperproliferative state is independent of the degree of inflammation and the duration of the disease, and exists even when the disease is in an inactive state, thus 25 suggesting an intrinsic abnormality of the colonic epithelium in ulcerative colitis. Biasco et al. *Cancer Res.* 1984, 44:5450-5454; Serafini et al. *Gut* 1981, 22:648-652. Similar hyperproliferative states have been observed in patients at risk for colonic malignancy such as in familial polyposis coli, 30 sporadic adenomas and familial nonpolyposis colon cancer. Risio, M. J. *Cell. Biochem.* 1992, 16G:79-87.

It has now been found that the ability of intestinal epithelial cells to respond to an inflammatory stimulus such as that resulting from ulcerative colitis is dependent on the 35 state of cell differentiation. It has been demonstrated that undifferentiated or pre-confluent Caco-2 cells can be stimulated by interleukin-1 $\beta$  (IL-1 $\beta$ ) to produce interleukin-8

- 7 -

(IL-8) mRNA. In contrast, differentiated or post-confluent cells produce very little IL-8 mRNA after stimulation. It has also been found that nutrients and their derivatives, such as butyrate and vitamin D, which are capable of inducing  
5 differentiation, inhibit the expression of inflammatory mediators by intestinal epithelial cells. Induction of Caco-2 cell differentiation using differentiating agents such as sodium butyrate or vitamin D inhibits the expression of IL-8.

Butyrate enemas have been used to reduce inflammation in  
10 patients with distal ulcerative colitis. Breuer et al. *Dig. Dis. Sci.* **1991**, 36:185-187; Scheppach et al. *Gastroenterology* **1992**, 103:51-56; Steinhart et al. *Am. J. Gastro.* **1994**, 89:179-183. In two studies, butyrate enemas were shown to result in a significant clinical response in patients whose disease did  
15 not respond to traditional forms of treatment including use of corticosteroids and 5-amino salicylic acid compounds. The basis of this response is unknown. Scheppach et al. observed that the labeling index of clonocytes in the upper crypt of patients with ulcerative colitis fell to that of normal healthy  
20 controls after treatment with butyrate enemas. However, the use of butyrate enemas is severely limited due to its extremely strong odor which leads to patients refusing to continue treatment.

The metabolically active form of vitamin D, 1,25-dihydroxyvitamin D<sub>3</sub> [1,25-(OH)<sub>2</sub>D<sub>3</sub>] or calcitrol, has also been  
25 recognized as a differentiation agent. This form of vitamin D not only plays a critical role in calcium and phosphorus homeostasis, but also inhibits cell proliferation and induces differentiation of multiple malignant as well as non-  
30 transformed cell types. Pols et al. *Clinical Endocrinology* **1994**, 40:285-291.

*In vitro* data have now demonstrated that differentiating agents such as sodium butyrate, sodium propionate, 1,25-(OH)<sub>2</sub>D<sub>3</sub>, and phenylacetate are capable of inducing intestinal epithelial  
35 cell differentiation concurrent with inhibiting gene expression for the proinflammatory cytokine IL-8. Tributyrin, a less noxious prodrug of sodium butyrate, has also been shown to lead

- 8 -

to an identical biological response *in vitro* at concentrations one third (1/3) that of sodium butyrate. These results were unexpected in light of *in vitro* experiments related to cytodifferentiation wherein it was found that tributyrin was only as effective as sodium butyrate in inhibiting cell proliferation at the same dose. Nudelman et al. *J. Med. Chem.* 1992, 35(4):687-694. Furthermore, these results suggest that colonic epithelial cells contain intracellular esterases that allow tributyrin to be metabolized to butyrate. No toxicity has been observed in mice treated with tributyrin either orally or intraperitoneally with a dose of 26.5 mmole/kg. Planlchon et al. *J. Pharm. Sci.* 1993, 82:1046-1048. In addition, tributyrin has been well tolerated in humans. For example, no detectable side effects were seen after six premature infants were fed butyrates for 4 days at doses of about 20 mmol/kg/day. Snyderman et al. *Arch Dis. Child.* 1955, 30:83-84.

In the present invention, a method is provided for decreasing the inflammation associated with a chronic inflammatory intestinal condition in a patient which comprises administering to a patient an effective amount of a differentiating agent. Examples of differentiating agents which can influence the inflammatory states of the intestine include, but are not limited to, polar/apolar compounds such as dimethyl sulfoxide and hexamethylene bisacetamide; retinoids such as 13-cis-retinoic acid, all-trans-retinoic acid and other analogs of retinol; vitamin D analogs including 1,25-(OH)<sub>2</sub>D<sub>3</sub>; histone hyperacetylators such as sodium butyrate and prodrugs thereof, sodium propionate and trichostatin A; hormones such as TGF- $\beta$  and glucocorticoids; antioxidants such as PDTC; peroxisome proliferators such as clofibrate; and miscellaneous differentiating agents such as phenylacetate and phenylbutyrate. By "effective amount" it is meant a concentration sufficient to decrease the inflammation in the intestine associated with the condition. Effective concentrations of a differentiating agents can be easily determined based upon the data provided in the instant disclosure and knowledge of those of skill in the art. By

- 9 -

"patient" it is meant an individual suffering from a chronic intestinal inflammatory condition. Examples of diseases or conditions which can be treated with the differentiating agents in accordance with the present invention include, but are not limited to, ulcerative colitis, Crohn's disease, Type A chronic gastritis, Type B chronic gastritis and graft vs. host disease (GVDH).

Once the inflammatory state has been initiated, an entire cascade of inflammatory mediators including cytokines, complement factors, prostaglandins, bradykinins and oxygen radicals follows. Accordingly, attempts to inhibit a single inflammatory pathway will not always lead to resolution of inflammation once the reaction has been initiated. An example of this is the inability of IL-1 receptor antagonists to induce clinical remission in patients with active ulcerative colitis. In contrast, antiinflammatory agents such as glucocorticoids which inhibit multiple inflammatory pathways simultaneously, have been shown to be very effective in the treatment of inflammatory disease of the bowel. Thus, it is believed that the administration of differentiating agents which inhibit the expression of inflammatory mediators by epithelial cells in conjunction with inhibitors of inflammatory mediators produced by immunocytes such as IL-1 receptor antagonist and cyclosporin, will result in a synergistic anti-inflammatory effect.

The following nonlimiting examples are provided to further illustrate the present invention.

#### EXAMPLES

##### Example 1: Induction of IL-8 mRNA in Caco-2 cells

Caco-2 cells (American Type Culture Collection, Rockville, Maryland) were plated at a density of  $4 \times 10^4$  cells per  $\text{cm}^2$  in 10 cm dishes containing Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum and penicillin/streptomycin as described by Wu et al. *J. Biol. Chem.* 1992, 267:7863-7870 and Traber et al. *Mol. Cell. Biol.* 1992, 12:3614-3627. At days 5 (pre-confluent state) and 18 (post-confluent

- 10 -

state) the cells were stimulated with complete medium containing 5 ng/ml of IL-1 $\beta$  (R and D Systems, Minneapolis, MN). Total RNA was isolated from these cells 2 and 4 hours after the addition of IL-1 $\beta$  containing medium as well as from a control cell population not treated with IL-1 $\beta$  in accordance with procedures described by Chomczynski, P. and Sacchi, N. *Anal. Biochem.* 1987, 162:156-159. Ten micrograms of RNA for each sample was electrophoretically separated, transferred to a nylon membrane, and UV crosslinked in accordance with procedures described by Traber et al. *Am. J. Physiol.* 1992, 262:G123-G130. A cDNA probe for IL-8 was prepared by RT-PCR of total RNA from Caco-2 cells stimulated with IL-1 $\beta$  for 2 hours. Random hexamers were used for reverse transcription of the RNA using reaction conditions similar to those described by Wu et al. *Gastroenterology* 1993, 105:837-844. A 277 bp cDNA was amplified from the RT reaction by PCR using the 5' primer IL-8(+103) and the 3' primer IL-8(EX4), cloned using a TA-vector (Marchuk et al. *Nuc. Acids Res.* 1991, 19:1154), and labeled with <sup>32</sup>P using a Random Primers DNA labeling System (Gibco BRL, Gaithersburg, MD). Hybridization of the Northern blots were performed using conditions as described by Huang et al. *Mol. Endo.* 1993, 7:1391-1398.

IL-8(+103) 5'-GTGGGATCCATGACTTCCAAGCTGGCC-3' (SEQ ID NO: 1)

IL-8(EX4) 5'-GTGGGATCCGAATTCTCAGCCCTCTTC-3' (SEQ ID NO: 2)

GGATCC indicates the BAM HI site.

Results are shown in Figure 1.

Figure 2 shows a second Northern blot using the same total RNA hybridized with a 1.3 kb (Eco RI/MluI) restriction fragment of the CCAAT/Enhancer Binding Protein delta (C/EBP $\delta$ ) isoform. Cao et al. *Genes and Develop.* 1991, 5:1538-1552. Both blots were subsequently stripped and rehybridized with a cDNA probe for 7S ribosomal RNA to demonstrate the loading and integrity of the RNA in each lane.

Stimulation of pre-confluent undifferentiated Caco-2 cells with IL-1 $\beta$  lead to a dramatic induction of IL-8 mRNA at 2 hours which rapidly decreased at late time points (see Figure 1). In contrast, stimulation of post-confluent differentiated

- 11 -

Caco-2 cells showed very minimal induction of IL-8 mRNA (see Figure 1). Hybridization of this same RNA using a probe for C/EBP $\delta$ , an immediate gene product of the inflammatory response, demonstrated that post-confluent Caco-2 cells actually produce greater amounts of this mRNA than pre-confluent cells. Thus, although post-confluent Caco-2 cells are still capable of responding to an inflammatory status, it appears that the expression of a gene encoding an inflammatory modulating substance such as IL-8 is differentially regulated. Furthermore, the C/EBP $\delta$  response of post-confluent cells suggests that functional IL-1 $\beta$  is present in the medium of post-confluent Caco-2 cells and that functional IL-1 $\beta$  receptors as well as a signal transduction pathway must still exist in post-confluent Caco-2 cells.

**Example 2: Inhibition of IL-1 $\beta$  stimulated IL-8 gene expression with differentiating agents**

Approximately 18 hours post-plating, Caco-2 cells were placed in complete medium containing various concentrations of sodium butyrate (Sigma Chemical Company, St. Louis, MO), sodium propionate (Sigma Chemical Company, St. Louis, MO), 1,25-(OH) $_2$ D $_3$  (Biomol Research Laboratories, Plymouth Meeting, PA) or phenylacetate (Sigma Chemical Company, St. Louis, MO). Caco-2 cells were also plated that were not treated with any of these compounds. The medium was changed on a daily basis for 3 days. On day 5 all the cells (except for control) were stimulated with IL-1 $\beta$  (5 ng/ml) for 2 hours. Total RNA was then isolated and Northern blots performed as described in Example 1. The blots were hybridized to the IL-8 cDNA probe also described in Example 1.

Increasing concentrations of sodium butyrate from 0.1 to 2.5 mM led to a dose dependent reduction in steady state levels of IL-8 mRNA. These concentrations of sodium butyrate were well-tolerated by Caco-2 cells without any evidence of cell death. Treatment of Caco-2 cells with sodium butyrate at concentrations higher than 2.5 mM, which caused significant toxicity and cell death, led to increased expression of IL-8 mRNA. Concurrent with maximal inhibition of IL-8 mRNA

- 12 -

expression at 2.5 mM is the induction of mRNA for alkaline phosphatase, a marker for intestinal epithelial cell differentiation.

Sodium propionate (0.1 to 20 mM) also inhibited IL-8 mRNA  
5 expression in a dose dependent fashion concurrent with the induction of alkaline phosphatase mRNA expression. In contrast to sodium butyrate, however, treatment of Caco-2 cells with the maximum concentration of sodium propionate studied, 20 mM, did not lead to cell toxicity or death.

10 1,25-(OH)<sub>2</sub>D<sub>3</sub> at concentrations of 10<sup>-8</sup> and 10<sup>-9</sup> also caused a decrease in steady state IL-8 mRNA expression. These concentrations of 1,25-(OH)<sub>2</sub>D<sub>3</sub> have also been shown to inhibit Caco-2 cell proliferation and induce markers of intestinal epithelial differentiation. Halline et al. *Endocrinology* 1994,  
15 134:1710-1717.

Dose dependent inhibition of IL-8 mRNA expression was also observed with phenylacetate at concentrations ranging from 2.5 to 10 mM. There was no evidence of Caco-2 cell toxicity at any concentration of phenylacetate studied.

20

- 13 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Gary Dean Wu
- (ii) TITLE OF INVENTION: DIFFERENTIATING AGENTS FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASES
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Jane Massey Licata, Esq.
  - (B) STREET: 210 Lake Drive East, Suite 201
  - (C) CITY: Cherry Hill
  - (D) STATE: NJ
  - (E) COUNTRY: USA
  - (F) ZIP: 08002
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
  - (B) COMPUTER: IBM 486
  - (C) OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
  - (D) SOFTWARE: WORDPERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: not yet assigned
  - (B) FILING DATE: Herewith
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/387,116
  - (B) FILING DATE: February 13, 1995
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Jane Massey Licata
  - (B) REGISTRATION NUMBER: 32,257
  - (C) REFERENCE/DOCKET NUMBER: PENN-0061



- 14 -

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (609) 779-2400

(B) TELEFAX: (609) 779-8488

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: No

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTGGGATCCATGACTTCCAAGCTGGCC

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: No

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GTGGGATCCGAATTCTCAGCCCTCTTC

- 15 -

**What is claimed is:**

1. A method for decreasing the inflammation associated with a chronic inflammatory intestinal condition in a patient comprising administering to a patient an effective amount of a  
5 differentiating agent.

2. The method of claim 1 wherein the differentiating agent is administered in conjunction with an inhibitor of inflammatory mediators produced by immunocytes.

1/1




FIG. 1

IL-1 $\beta$	0	+	+	+	+
Tributyrin (mM)	0	0	0.1	0.5	1.0



FIG. 2

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/04348**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07C 51/09; C08F 22/14; C12N 15/25

US CL : 514/2, 506, 786, and 885

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 506, and 885

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS and CAPLUS: tributyrin, chronic inflammatory bowel disease, interleukin-1, IL-1, colitis

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BREUER et al. Rectal Irrigation with Short-Chain Fatty Acids for Distal ulcerative Colitis. Dig. Dis. Sci. February 1991, Vol. 36, Number 2, pages 185 - 187, especially page 185 and 187.	1 - 2
Y	SCHEPPACH et al. Effect of Butyrate Enemas on Colonic Mucosa in Distal Ulcerative Colitis. Gastroenterology. 1992, Vol. 103, pages 51 - 56, especially pages 51 and 56.	1 - 2
Y	STEINHART et al. Treatment of Refractory Ulcerative Proctosigmoiditis with Butyrate Enemas. Am. J. Gastro. February 1994, Vol. 89, Number. 2 pages 179 - 183, especially pages 179 and 183.	1 - 2

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 26 JUNE 1996	Date of mailing of the international search report 17 JUL 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer GARY L. KUNZ Telephone No. (703) 308-1235

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/04348

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DESCHNER et al. Dietary butyrate (tributylin) does not enhance AOM-induced colon tumorigenesis. Cancer Letters. 1994, Vol. 52, pages 79 - 82, especially pages 79 and 82.	1 - 2
Y	CHEN et al. Tributyrin: A Prodrug of Butyric Acid for Potential Clinical Application in Differentiation Therapy. Cancer Research. 1994, pages 3494 - 3499, especially pages 3494 and 3499.	1 - 2
Y	POLS et al. Vitamin D analogues: from molecule to clinical application. Clinical Endocrinology. 1994, vol. 40, 285 - 291, especially pages 285 and 291.	2
Y	RADEMA et al. Interleukin 1B is Expressed Predominantly by Enterocytes in Experimental Colitis. Gastroenterology. 1991, Vol. 100, pages 1180 - 1186, especially page 1180.	2